| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
The recent report revealed that 4.6 million Japanese suffer with dementia and more than 4 million, with minimal cognitive impairment. This huge number by this etiological research surprised us and the establishment of fundamental therapeutics of Alzheimer's disease is strongly desired in Japan as well as in the countries where the aged are increasing. A lot of evidence have realized that the increase in amyloid beta is a culprit. The genetic modulation of Abeta production in mice mimics the AD brain pathology and deteriorates the cognitive function. This study identified the novel modulating protein of Abeta producing enzyme. The identified modulator is specific to Abeta production, not to another pivotal Notch production. We also confirmed that transgenic mouse of the novel modulator decreased Abeta production in the mouse brain. These findings suggest that the identified modulator is a therapeutic target of AD.
|
